Investor news
No. 10/2018

Orphazyme A/S
Ole Maaløes Vej 3
DK-2200 Copenhagen N

www.orphazyme.com
Company Registration No. 32266355

Orphazyme to Present at InvestorDagen 2018

Copenhagen, September 18, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders Hinsby, Chief Executive Officer at Orphazyme, will be presenting at Dansk Aktionærforening's InvestorDagen in Copenhagen, Denmark, today, September 18, 2018 at 10.20 AM CET.

For free participation, please visit www.InvestorDagen.dk and use the code VIPOrphazyme2018.

For additional information, please contact

Orphazyme A/S
Anders Hinsby, CEO +45 31 44 31 39

About Orphazyme A/S
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company's lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.